Treatment of anaerobic infection

References

• Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe12, 115–121 (2006).
   PubMed Web of Science ®Google Scholar
• Altemeier WA, Fullen WD. Prevention and treatment of gas gangrene. JAMA217, 806–813 (1971).
   PubMed Web of Science ®Google Scholar
• Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin. Infect. Dis.15(43), 188–192 (2006).
   Google Scholar
• Kindwall EP. Use of hyperbaric oxygen therapy in the 1990s Cleveland clinic. J. Med.59, 517–528 (1992).
   Google Scholar
• Nakajima H, Iwai Y, Yamanaka K, Kishi H. Successful treatment of brainstem abscess with stereotactic aspiration. Surg. Neurol.52, 445–448 (1999).
   PubMedGoogle Scholar
• Pruitt AA. Infections of the nervous system. Neurol. Clin.16, 419–447 (1998).
   PubMed Web of Science ®Google Scholar
• Brook I, Walker RI. Significance of encapsulated Bacteroides melaninogenicus and Bacteroides fragilis groups in mixed infections. Infect. Immun.44, 12–14 (1984).
   PubMed Web of Science ®Google Scholar
• Cinat ME, Wilson SE. New advances in the use of antimicrobial agents in surgery: intra-abdominal infections. J. Chemother.11, 453–463 (1999).
   Google Scholar
• Finegold SM, George WL, Mulligan ME. Anaerobic Infections. Disease a Month (Volume 31). Yearbook Medical Publisher Inc., IL, USA 11–17 (1985).
   Google Scholar
• Verklin RM, Mandell GL. Alteration of antibiotics by anaerobiosis. J. Lab. Clin. Med.89, 65–71 (1977).
   PubMed Web of Science ®Google Scholar
• Gorbach SL, Bartlett JG. Anaerobic infections. N. Engl. J. Med.290, 1177–1184 (1974).
   PubMed Web of Science ®Google Scholar
• Aldridge KE, Sanders CV. Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole. Anaerobe8, 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob. Agents Chemother.10, 736–752 (1976).
   PubMed Web of Science ®Google Scholar
• Brook I, Gober AE. Emergence of β-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin. Pediatr.23, 338–342 (1984).
   PubMed Web of Science ®Google Scholar
• Tuner K, Nord CE. Emergence of β-lactamase-producing microorganisms in the tonsils during penicillin treatment. Eur. J. Clin. Microb.5, 399–404 (1986).
   PubMedGoogle Scholar
• Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of B. fragilis group: report and analysis of trends for 1997–2004: a US survey. Antimicrob. Agents Chemother.1649–1655 (2007).
   PubMed Web of Science ®Google Scholar
• Labbe AC, Bourgault AM, Vincelette J, Turgeon PL, Lamothe F. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob. Agents Chemother.43, 2517–2519 (1999).
   PubMed Web of Science ®Google Scholar
• Bianchini H, Fernandez Canigia LB, Bantar C, Smayevsky J. Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina. Clin. Infect. Dis.25, S268–S269 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia-Rodrigues JE, Garcia-Sanchez JE. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. Clin. Infect. Dis.12, S142–S151 (1990).
   Google Scholar
• Lee KY, Chuong SH, Jeong X-S et al. Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Clin. Infect. Dis.23, S73–S77 (1996).
   PubMed Web of Science ®Google Scholar
• Finegold SM. Anaerobic Bacteria in Human Disease. Academic Press, NY, USA (1977).
   Google Scholar
• Busch DF, Kureshi LA, Sutter VL, Finegold SM. Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins. Antimicrob. Agents Chemother.10, 713–720 (1976).
   PubMed Web of Science ®Google Scholar
• Finegold SM. In vitro efficacy of β-lactam/β-lactamase inhibitor combinations against bacteria involved in mixed infections. Int. J. Antimicrob. Agents12(Suppl. 1), S9–S14 (1999).
   PubMed Web of Science ®Google Scholar
• Acuna C, Rabasseda X. Amoxicillin– sulbactam: a clinical and therapeutic review. Drugs Today (Barcelona)37, 193–210 (2001).
   PubMed Web of Science ®Google Scholar
• Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to carbenicillin, cefoxitin, and related drugs. J. Infect. Dis.131, 417–422 (1975).
   PubMed Web of Science ®Google Scholar
• Fiedelman W, Webb CD. Clinical evaluation of carbenicillin in the treatment of infection due to anaerobic bacteria. Curr. Ther. Res.18, 441–451 (1975).
   PubMed Web of Science ®Google Scholar
• Thadepalli H, Huang JT. Treatment of anaerobic infections: carbenicillin alone compared with clindamycin and gentamicin. Curr. Ther. Res.22, 549–557 (1977).
   Web of Science ®Google Scholar
• Brook I. Carbenicillin in treatment of aspiration pneumonia in children. Curr. Ther. Res.23, 136–147 (1978).
   Web of Science ®Google Scholar
• Brook I. Anaerobic isolates in chronic recurrent suppurative otitis media: treatment with carbenicillin alone and in combination with gentamicin. Infection5, 247–251 (1979).
   Google Scholar
• Tally FP, Jacobus NV, Bartlett JG, Gorbach SL. In vitro activity of penicillins against anaerobes. Antimicrob. Agents Chemother.7, 413–414 (1975).
   PubMed Web of Science ®Google Scholar
• Roy I, Bach V, Thadepalli H. In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin. Antimicrob. Agents Chemother.11, 258–261 (1977).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Vaidya SA et al. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. Anaerobe12, 63–66 (2006).
   PubMed Web of Science ®Google Scholar
• Jousimies H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic Gram-negative bacteria (excluding spirochetes). Clin. Infect. Dis.1(Suppl. 1), S17–S21 (2002).
   Google Scholar
• Jousimies-Somer HR, Summanen P, Baron EJ, Citron DM, Wexler HM, Finegold SM. Wadsworth-KTL Anaerobic Bacteriology Manual (6th Edition). Star Publishing, CA, USA (2002).
   Google Scholar
• Brook I. Intra-abdominal, retroperitoneal, and visceral abscesses in children. Eur. J. Pediatr. Surg.14, 265–273 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin. Infect. Dis.35(Suppl. 1), S106–S111 (2002).
   PubMed Web of Science ®Google Scholar
• Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect.9, 475–488 (2003).
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother.43, 2417–2422 (1999).
   PubMed Web of Science ®Google Scholar
• Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J. Antimicrob. Chemother.58, 916–929 (2006).
   PubMed Web of Science ®Google Scholar
• Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin. Proc.74, 420–434 (1999).
   PubMed Web of Science ®Google Scholar
• Edwards JR. Meropenem: a microbiological overview. J. Antimicrob. Chemother.36, 1–17 (1995).
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli. Antimicrob. Agents Chemother.35, 2410–2414 (1991).
   PubMed Web of Science ®Google Scholar
• Abramowicz M. Meropenem – a new parenteral broad-spectrum antibiotic. Med. Lett.38, 88–90 (1996).
   Google Scholar
• Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs65, 2151–2178 (2005).
   PubMed Web of Science ®Google Scholar
• Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin. Proc.74, 825–833 (1999).
   PubMed Web of Science ®Google Scholar
• Thadepalli H, Gorbach SL, Bartlett JG. Apparent failure of chloramphenicol in anaerobic infections. Obstet. Gynecol. Surg.35, 334–335 (1978).
   Google Scholar
• Balbi HJ. Chloramphenicol: a review. Pediatr. Rev.25, 284–288 (2004).
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin. Pharmacokinet.35, 223–246 (1998).
   PubMed Web of Science ®Google Scholar
• Drutz DJ, Schaffner W, Hillman JW, Koenig MG. The penetration of penicillin and other antimicrobials into joint fluid. J. Bone Joint Surg.49, 1415–1421 (1967).
   PubMed Web of Science ®Google Scholar
• Joiner KA, Lowe BR, Dzink JL, Bartlett JG. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J. Infect. Dis.143, 487–494 (1981).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared with those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob. Agents Chemother.43, 1469–1474 (1999).
   PubMed Web of Science ®Google Scholar
• Williams JD, Maskell JP, Shain H et al. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J. Antimicrob. Chemother.30, 27–37 (1992).
   PubMed Web of Science ®Google Scholar
• Sanai Y, Persson GR, Starr JR et al. Presence and antibiotic resistance of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in children. J. Clin. Periodontol.29, 929–934 (2002).
   PubMed Web of Science ®Google Scholar
• Finegold SM, Harada NE, Miller LG. Lincomycin activity against anaerobes and effect on normal human fecal flora. Antimicrob. Agents Chemother.5, 659–667 (1965).
   PubMedGoogle Scholar
• Klainer AS. Clindamycin. Med. Clin. North Am.71, 1169–1175 (1987).
   PubMed Web of Science ®Google Scholar
• LeFrock JL, Molavi A, Prince RA. Clindamycin. Med. Clin. North Am.66, 103–120 (1982).
   PubMed Web of Science ®Google Scholar
• Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet.19, 280–318 (1990).
   PubMed Web of Science ®Google Scholar
• Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PG. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics55, 213–223 (1975).
   PubMed Web of Science ®Google Scholar
• Novak E, Wagner JG, Lamb DJ. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration. Int. Z. Klin. Pharmakol. Ther. Toxikol.3, 201–208 (1970).
   PubMedGoogle Scholar
• Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol.12, 259–262 (1972).
   Web of Science ®Google Scholar
• Gorbach SL, Thadepalli H. Clindamycin in the treatment of pure and mixed anaerobic infections. Arch. Intern. Med.134, 87–92 (1974).
   PubMedGoogle Scholar
• Gorbach SL. Antibiotics and Clostridium difficile. N. Engl. J. Med.341, 1690–1691 (1999).
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile – associated diarrhea: a review. Arch. Intern. Med.161, 525–533 (2001).
   PubMed Web of Science ®Google Scholar
• Devenyi AG. Antibiotic-induced colitis. Semin. Pediatr. Surg.4, 215–220 (1995).
   PubMedGoogle Scholar
• Berlatzky Y, Rubin SZ, Michel J, Sacks T, Schiller M. Use of clindamycin and gentamicin in pediatric colonic surgery. J. Pediatr. Surg.11, 83–94 (1976).
   PubMed Web of Science ®Google Scholar
• Brook I. Clindamycin in treatment of aspiration pneumonia in children. Antimicrob. Agents Chemother.15, 342–344 (1979).
   PubMed Web of Science ®Google Scholar
• Brook I. Bacteriology and treatment of chronic otitis media in children. Laryngoscope89, 1129–1134 (1979).
   PubMed Web of Science ®Google Scholar
• Brook I, Yocum P. Antimicrobial management of chronic sinusitis in children. J. Laryngol. Otol.109, 1159–1162 (1995).
   PubMed Web of Science ®Google Scholar
• Brook I, Lewis MA, Sandor GK, Jeffcoat M, Samaranayake LP, Vera Rojas J. Clindamycin in dentistry: more than just effective prophylaxis for endocarditis? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.100, 550–558 (2005).
   PubMed Web of Science ®Google Scholar
• Chow AW, Patten V, Guze LB. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore forming Gram-positive bacilli. J. Infect. Dis.131, 182–185 (1975).
   PubMed Web of Science ®Google Scholar
• Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs54, 679–708 (1997).
   PubMed Web of Science ®Google Scholar
• Rustia M, Shubik P. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT)BR rats. J. Natl Cancer Instit.63, 863–868 (1979).
   PubMed Web of Science ®Google Scholar
• Cohen SM, Erturk E, Von Esch AM, Crovetti AJ, Bryan GT. Carcinogenicity of 5-nitro-furans 5-nitromidazoles, 4-nitrobenzenes and related compounds. J. Natl Cancer Instit.51, 403–417 (1973).
   PubMed Web of Science ®Google Scholar
• Beard CM, Noller KL, O’Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N. Engl. J. Med.301, 519–522 (1979).
   PubMed Web of Science ®Google Scholar
• Tally FP, Gorbach SL. Therapy of mixed anaerobic–aerobic infections. Lessons from studies of intra-abdominal sepsis. Am. J. Med.7(78), 145–153 (1985).
   Google Scholar
• Berman BW, King FH Jr, Rubenstein DS, Long SS. Bacteroides fragilis meningitis in a neonatal successfully treated with metronidazole. J. Pediatr.93, 793–795 (1979).
   Web of Science ®Google Scholar
• Sørensen HT, Larsen H, Jensen ES et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J. Antimicrob. Chemother.44, 854–855 (1999).
   PubMed Web of Science ®Google Scholar
• Brook I. Treatment of anaerobic infections in children with metronidazole. Dev. Pharmacol.6, 187–198 (1983).
   PubMedGoogle Scholar
• Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int. J. Clin. Pract.60(12), 1662–1672 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob. Agents Chemother.50, 3507–3513 (2006).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Quinolone activity against anaerobes. Drugs58, 60–64 (1999).
   PubMed Web of Science ®Google Scholar
• Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin. Infect. Dis.42, 1598–1607 (2006).
   PubMed Web of Science ®Google Scholar
• Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs51, 31–37 (1996).
   PubMed Web of Science ®Google Scholar
• Brook I. Pathogenicity and management of polymicrobial infections due to aerobic and anaerobic bacteria. Med. Res. Rev.15, 73–82 (1995).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Recent developments in the management of anaerobic infection. Rev. Inf. Dis.5, 235–245 (1983).
   PubMedGoogle Scholar
• Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections – a review on randomised clinical trials. Eur. J. Med. Res.30(6), 277–291 (2001).
   Google Scholar
• Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg. Infect. (Larchmt)6, 329–333 (2005).
   PubMedGoogle Scholar
• Sanabria A. Decision-making analysis for selection of antibiotic treatment in intra-abdominal infection using preference measurements. Surg. Infect. (Larchmt)7, 453–462 (2006).
   PubMedGoogle Scholar
• Laterre PF, Colardyn F, Delmee M et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir. Belg.106, 2–21 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall JC. Intra-abdominal infections. Microbes Infect.6, 1015–1025 (2004).
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Kanellakopoulou K. Bacteriologic and therapeutic considerations in intra-abdominal surgical infections. Anaerobe3, 207–212 (1997).
   PubMed Web of Science ®Google Scholar
• Verwaest C; Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin. Microbiol. Infect.6, 294–302 (2000).
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother.8, 237–256 (2007).
   PubMed Web of Science ®Google Scholar
• Munckhof WJ, Carney J, Neilson G et al. Continuous infusion of ticarcillin– clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents25, 514–522 (2005).
   PubMed Web of Science ®Google Scholar
• Powell LL, Wilson SE. The role of β-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg. Infect. (Larchmt)1, 57–63 (2000).
   PubMedGoogle Scholar
• Brook I, Coolbaugh JC, Walker RI, Weiss E. Synergism between penicillin, clindamycin or metronidazole and gentamicin against species of Bacteroides melaninogenicus and fragilis groups. Antimicrob. Agents Chemother.25, 71–77 (1984).
   PubMed Web of Science ®Google Scholar
• Acar JF. Antibiotic synergy and antagonism. Med. Clin. North Am.84, 1391–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997–2000. Clin. Infect. Dis.35(Suppl. 1), S126–S134 (2002).
   PubMed Web of Science ®Google Scholar
• Bergan T, Fotland MH. In vitro interactions between metronidazole or tinidazole and co-trimoxazole on the effect against anaerobic bacteria. Scand. J. Gastroenterology19(Suppl.) 95 (1984).
   Google Scholar
• Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob. Agents Chemother.17, 379 (1980).
   PubMed Web of Science ®Google Scholar
• Busch DF, Sutter VL, Finegold SM. Activity of combinations of antimicrobial agents against Bacteroides fragilis. J. Infect. Dis.133, 321–328 (1976).
   PubMed Web of Science ®Google Scholar
• Brook I. Metronidazole and spiramycin in abscesses caused by Bacteroides spp. Staphylococcus aureus in mice. J. Antimicrob. Chemother.20, 713–718 (1987).
   PubMed Web of Science ®Google Scholar
• Videau D, Blanchard JC, Sebald M. Bucco-dental flora. Sensitivity to antibiotics and value of the spiramycin–metronidazole combination. Ann. Microbiol.1248, 505–516 (1973).
   Google Scholar
• Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J. Antimicrob. Chemother.45, 633–638 (2000).
   PubMed Web of Science ®Google Scholar
• Credito KL, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn. Microbiol. Infect. Dis.38, 181–183 (2000).
   PubMed Web of Science ®Google Scholar
• Fass RJ, Rotilie CA, Prior RB. Interaction of clindamycin and gentamicin in vitro. Antimicrob. Agents Chemother.6, 582–587 (1974).
   PubMed Web of Science ®Google Scholar
• Okubadejo OA, Allen J. Combined activity of clindamycin and gentamicin on Bacteroides fragilis and other bacteria. J. Antimicrob.Chemother.1, 403–409 (1975).
   PubMedGoogle Scholar
• Brook I, Walker RI. Interaction between penicillin, clindamycin or metronidazole and gentamicin against species of clostridia and anaerobic and facultative anaerobic Gram-positive cocci. J. Antimicrob. Chemother.15, 31–37 (1985).
   PubMed Web of Science ®Google Scholar
• Bryan LE, Kowand SK, Den Elzen HM. Mechanisms of aminoglycoside antibiotic resistance in anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrob. Agents Chemother.15, 7–13 (1979).
   PubMedGoogle Scholar
• Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin. Infect. Dis.44, 895–900 (2007).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis.30, 870–876 (2000).
   PubMed Web of Science ®Google Scholar